In a preferred embodiment of the invention, the CNS pathology is one of a peripheral disorder with a CNS component, such as septic shock, brain metastasis, hepatic encephalopathy, (diabetic) hypertension, diabetic (micro)angiopathy, sleeping sickness, Whipple disease, Duchenne muscular dystrophy (DMD), aspartylglucosaminuria, cholesterol ester storage disease, Wolman disease, cystinosis, Danon disease, Fabry disease, Farber lipogranulomatosis, Farber disease, fucosidosis, galactosialidosis types I/II, Gaucher disease types I/II/III, Gaucher disease, globoid cell leuco dystrophy, Krabbe disease, glycogen storage disease II, Pompe disease, GMl- gangliosidosis types 1/11/1 II, GM2-gangliosidosis type I, Tay Sachs disease, GM2- gangliosidosis type II, Sandhoff disease, GM2-gangliosidosis, alpha-mannosidosis types 1/1 1 , mannosidosis, metachromatic leucodystrophy, mucolipidosis type I, sialidosis types 1/11 mucolipidosis types l l/III 1-cell disease, mucolipidosis type UIC pseudo-Hurler poly dystrophy, mucopolysaccharidosis type I, mucopolysaccharidosis type II, Hunter syndrome, mucopolysaccharidosis type IIIA, Sanflippo syndrome, mucopolysaccharidosis type IHB, mucopolysaccharidosis type IHC, mucopolysaccharidosis type HID, mucopolysaccharidosis type IVA, Morquio syndrome, mucopolysaccharidosis type IVB Morquio syndrome, mucopolysaccharidosis type VI, mucopolysaccharidosis type VII, Sly syndrome, mucopolysaccharidosis type IX, multiple sulphatase deficiency, neuronal ceroid lipofuscinosis, CLNl Batten disease, Niemann-Pick disease types A/B, Niemann-Pick disease, Niemann-Pick disease type Cl, Niemann-Pick disease type C2 , pycnodysostosis, Schindler disease types VII, Schindler disease, sialic acid storage disease, and (pre)eclampsia
Local administration is commonly used because its effects appear strongest close to the target tissue
As with all medications, certain adverse effects from Tesamorelin may occur, typically not warranting immediate medical attention by the patient
Inhibiting ferroptosis through disrupting the NCOA4FTH1 interaction: a new mechanism of action
Appropriate for individuals whose healthcare provider has determined a higher thyroid glandular dose is appropriate.*
